Capital International Sarl Adagene Inc. Transaction History

Capital International Sarl

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.99 - $3.85 $56,500 - $109,309	-28,392 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$11.8 - $17.87 $86,541 - $131,058	-7,334 Reduced 20.53%	28,392 $385,000
Q1 2021 May 14, 2021	BUY	$17.0 - $29.99 $607,342 - $1.07 Million	35,726 New	35,726 $641,000

9.87M

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $86.4M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

Get notified when there are updates to the investment portfolio of Capital International Sarl, based on Form 13F filings with the SEC.

Stay updated on Capital International Sarl with notifications on news.